A Phase 1 interventional study of MSK-DA01 and MSK-DA01 Cell Delivery Device in Advanced Parkinson's Disease, sponsored by BlueRock Therapeutics. Completed at 3 sites in 2 countries. Open to participants aged 50 Years to 78 Years. Per ClinicalTrials.gov, last updated 2024-11-01.
Sponsored by BlueRock Therapeutics (part of Bayer) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Parkinson Disease by Bayer — 6 open to participants now, 8 under way, 1 of them phase 3. Parkinson Disease · Bayer.
Among the 12 studies in Parkinson Disease by Bayer, this one is the only one that started in 2021, is the only one in phase 1, and was the 3rd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →6 of the 12 studies in Parkinson Disease by Bayer are open now, in 4 countries. Recruiting first, the newest first:
Bayer · Sites in United States
Ages 45–75
BlueRock Therapeutics · Sites in United States, Australia, Canada
Ages 45–75
AskBio Inc · Sites in United States
BlueRock Therapeutics · Sites in United States, Canada
Ages 50–78
Bayer · Sites in Japan
Ages 45–75
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 50 Years to 78 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2021.
This study's enrollment of 12 is below the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 18 across the 7 interventional studies, 132 across the 5 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under BlueRock Therapeutics, one of the names counted as Bayer. Under that name alone:
BlueRock Therapeutics is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
1 of the studies in Parkinson Disease by Bayer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05897957BlueRock TherapeuticsContinued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01 | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Parkinson Disease by Bayer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.
Subjects will undergo surgical transplantation of the dopamine-producing cells under general anesthesia into a part of the brain called the putamen. Subjects then take medicines to partially suppress their immune system (aimed to prevent the body from rejecting the cells) for 1 year. Safety, tolerability, evidence of cell survival (using MRI and PET scans of the brain), and effect on Parkinson's disease symptoms are assessed for 2 years post-transplant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: MSK-DA01 · Device: MSK-DA01 Cell Delivery Device
MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.
A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.
Safety and Tolerability
The incidence of Serious Adverse Events (SAEs) at 1 year post-transplant. or abnormal tissue overgrowth related to presence of transplanted cells;
Time frame: Baseline to 1 Year Post-Transplant
Evidence of Cell Survival
Change in 18F-DOPA uptake using positron emission tomography (PET) from baseline to 1 and 2 years
Time frame: Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant
Changes in Motor Function
Changes in MDS-Unified Parkinson's Disease Rating Scale (UPDRS) motor sub-score in the "off" state from baseline to 2 years post-transplant.
Time frame: Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant
Changes in Waking Hours in "Off" State
Changes in number of waking hours in the "off" state from baseline to 2 years post-transplant.
Time frame: Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant
Continued Safety and Tolerability
Incidence of SAEs at 2 years post-transplant and incidence and type of AEs at 1 and 2 years post-transplant.
Time frame: Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2021 to primary completion in May 2023, 24 months.
Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 24 months is above that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.